Qiagen (NYSE:QGEN) Upgraded to “Buy” at Wall Street Zen

Wall Street Zen upgraded shares of Qiagen (NYSE:QGEN) from a hold rating to a buy rating in a report issued on Saturday.

Other research analysts have also recently issued research reports about the company. Cowen restated a “hold” rating on shares of Qiagen in a research note on Thursday, August 7th. Barclays set a $53.00 target price on shares of Qiagen and gave the company an “overweight” rating in a report on Thursday, October 2nd. Weiss Ratings reiterated a “hold (c+)” rating on shares of Qiagen in a research note on Wednesday, October 8th. Finally, UBS Group lifted their price target on shares of Qiagen from $48.00 to $50.00 and gave the company a “neutral” rating in a research report on Thursday, August 7th. Three research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat, Qiagen currently has a consensus rating of “Hold” and a consensus target price of $49.69.

Qiagen Stock Up 1.1%

Shares of NYSE QGEN opened at $46.86 on Friday. The firm has a fifty day simple moving average of $46.82 and a two-hundred day simple moving average of $46.39. Qiagen has a 12 month low of $37.63 and a 12 month high of $51.88. The company has a current ratio of 1.61, a quick ratio of 1.35 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $10.42 billion, a PE ratio of 27.68, a price-to-earnings-growth ratio of 2.48 and a beta of 0.66.

Qiagen (NYSE:QGEN) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.60. Qiagen had a net margin of 18.30% and a return on equity of 14.77%. The company had revenue of $533.54 million for the quarter, compared to analysts’ expectations of $523.97 million. During the same quarter in the previous year, the company earned $0.55 earnings per share. Qiagen’s quarterly revenue was up 7.7% on a year-over-year basis. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. Equities analysts expect that Qiagen will post 2.26 earnings per share for the current year.

Hedge Funds Weigh In On Qiagen

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD increased its holdings in shares of Qiagen by 3,030.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,470,728 shares of the company’s stock worth $179,501,000 after purchasing an additional 4,327,934 shares in the last quarter. Norges Bank purchased a new stake in shares of Qiagen during the second quarter valued at $158,728,000. Wellington Management Group LLP increased its holdings in Qiagen by 12.2% in the 1st quarter. Wellington Management Group LLP now owns 24,438,441 shares of the company’s stock worth $972,191,000 after buying an additional 2,656,136 shares in the last quarter. Deutsche Bank AG raised its position in Qiagen by 57.5% in the 1st quarter. Deutsche Bank AG now owns 4,491,131 shares of the company’s stock worth $180,319,000 after buying an additional 1,639,621 shares during the last quarter. Finally, Nuveen LLC bought a new position in Qiagen during the 1st quarter valued at about $44,078,000. 70.00% of the stock is owned by institutional investors.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.